I think that the sessions have been extremely interesting and provocative. It would be a shame to end the meeting without an opportunity to raise further questions, and to tie some issues together between the various sessions, such as relationships between the clinical and basic issues. There are many interesting loose ends, perhaps related to neural transplantation in general or to specific issues raised in the various sessions, that it would be useful to try to tie together. At the same time, because we have a large audience and hopefully many of you have important things to say, we are going to set some ground rules for the discussion that will give everybody an opportunity to speak. Therefore, we have chosen some specific topics as a way of beginning the discussion, and then we will open the discussion to the floor. We are going to ask the people who are speaking to limit themselves to 2 minutes so that everyone or nearly everyone can get an opportunity to speak.
The first issue in which several people have expressed a significant interest, is a continuation of the discussion concerning the design of clinical trials, and what do we need to do next to move the field forward. I have had a request from Patrick Aebischer to start that discussion. Those interested in the lesion trials will almost certainly use the CAPIT scheme, so there will be a regularity and uniformity of approach, in which case the lesions can be compared to transplantation studies. As long as we all do the same assessments, it will be all right it does not have to be the same group doing it which is the whole point of the CAPIT scheme.
Olle Lindvall: It Let us now move on to a final topic for general discussion that some people brought up informally over the last few days. We started to see glimmers of this around the time of the Third Intenational Meeting in Cambridge and a bit earlier, and it has really grown very impressively to maturity here. Perhaps not full maturity as yet, but adolescence certainly. This is the application of genetic engineering and immortalization techniques to cells that are to be transplanted. Perhaps we could now have some comments about that.
Richard Robbins:
There are a number of very important issues to consider when dealing with these kinds of approaches for cell transplantation. Obviously, one of the most important is that many of the genes that are introduced in order to help cells divide are in the category of oncogenes, and these can actually induce a condition of transformation. Such transformed cells may have anywhere from a small to a large capacity to continue to divide in the central nervous system. The development of, for instance, temperature-sensitive oncogenes such as those described by Ron McKay and co-workers at this meeting/4/is a significant advance in trying to overcome this problem. Another category of genes that don't normally induce a transformed phenotype, called immortalizing genes, have begun to be explored as a possible way to turn a switch on in a cell to make it divide. Such immortalized cells may continue to produce their own native factors or biologically active molecules. Genes such as the adenorviral E1A gene are an example. There are some new genes coming down the pike that might not have the transforming potential, and could potentially be useful for development of cell lines.
I think that one of the other general approaches that might need to be considered carefully here is whether or not we can simply transplant cells that have been modified to overproduce one growth factor or one neurotransmitter in an unregulated way, as opposed to implanting cells that have a neuronal phenotype and may be able to make appropriate synaptic connections and release either proteins or small neurotransmitters in a regulated way.
A major issue that one should consider when trying to create cell lines, is that there are two fundamentally different approaches. You can start with the cell that you want and add on gene that helps that cell divide, hopefully changing its phenotype as little as possible. Alternatively, you can take cells that can be genetically manipulated quite easily, and introduce the gene, for instance, for tyrosine hydroxylase, to try to get that cell to make dopamine. I think we are obviously going to have to demonstrate that any cell that makes a certain factor can be transplanted not only into rodents but primates with a great deal of safety before we will be able to approach our institutional review boards or human safety committees to convince them that we will be able to put these cells into a human and have absolutely no chance of forming a tumor. We would like to close this discussion by expressing our graditude to the organizers, the audience, and all of the participants for an enlightening and stimulating meeting. I think that everyone has done a wonderful job. There was a lot of effort involved in organizing this meeting, and we want to thank all of you very much for participating.
